Lucid Diagnostics Reports Q3 2025 Revenue Increase but Continued Operational Losses

Lucid Diagnostics Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a slight increase in revenue but continued operational losses. The company generated $1.2 million in revenue for the third quarter, a marginal increase from $1.17 million in the same period last year. For the nine months, total revenue reached $3.2 million, compared to $3.1 million in the prior year. Despite this revenue growth, Lucid Diagnostics incurred a net loss of approximately $10.4 million for the third quarter, an improvement from a net loss of $12.4 million in the same quarter of 2024. The nine-month net loss attributable to common stockholders was $54.3 million, compared to $41.5 million for the same period in 2024.

The company’s operating expenses for the third quarter totaled $12.97 million, slightly up from $12.87 million in the previous year. Notably, sales and marketing expenses increased to $4.29 million from $4.06 million, primarily due to higher third-party professional services. General and administrative expenses also rose to $5.61 million from $5.36 million, driven by increased professional fees. Research and development costs decreased to $1.27 million from $1.67 million, reflecting reduced clinical trial activities. The cost of revenue remained stable at approximately $1.7 million for both periods.

Lucid Diagnostics has made significant strides in its strategic initiatives, including the launch of its EsoGuard Esophageal DNA Test, which is designed for the early detection of esophageal precancer. The company has also expanded its market presence, recently partnering with Hoag Comprehensive Esophageal Precancer Testing Program to integrate EsoGuard testing into its healthcare offerings. Additionally, the company has been active in securing insurance reimbursements, with Highmark Blue Cross Blue Shield issuing a positive coverage policy for EsoGuard in New York.

As of September 30, 2025, Lucid Diagnostics reported total assets of $53.2 million, up from $30.7 million at the end of 2024, largely due to successful capital raises through various offerings. The company raised approximately $27 million from a confidentially marketed public offering in September 2025, following earlier offerings that generated $16.2 million in April and $14.9 million in March. Despite these capital inflows, the company continues to face challenges, including a significant accumulated deficit of $258.1 million and ongoing operational losses. Looking ahead, Lucid Diagnostics anticipates continued losses and negative cash flows, emphasizing the need for further revenue generation and potential additional financing to sustain operations.